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LETTERS TO THE EDITOR
The EXercise versus Angioplasty in Claudication
Trial (EXACT): Reasons for recruitment failure
and the implications for research into and
treatment of intermittent claudication
The options for subjects with infrainguinal peripheral arte-
rial disease (PAD) who remain unacceptably symptomatic de-
spite best medical therapy are specific pharmacotherapy, balloon
angioplasty, supervised exercise therapy, or surgery. Unfortu-
nately, there is little or no evidence base regarding the absolute
or relative clinical and cost-effectiveness of these adjuvant treat-
ments.1-3
The EXercise versus Angioplasty in Claudication Trial
(EXACT) was a UK Health Technology Assessment (HTA)
Programme multicenter, randomized-controlled trial designed
to compare the adjuvant benefits over best medical therapy of
supervised exercise and balloon angioplasty in patients with
mild-to-moderate intermittent claudication due to infraingui-
nal disease.
After persistent difficulties in recruitment at all four centers,
the trial was closed early in late 2004 at a point where only 10%
of the required patients had been entered. This report outlines
the details of the recruitment problems in one center and
discusses their implication for future trials.
Reasons for nonrecruitment at the initial screening assess-
ment are detailed in the Fig. Thus of 372 screened patients at
the close of the trial in September 2004, only 23 (6%) had been
randomized.
The following specific issues are worthy of discussion:
1. Almost one quarter of the patients referred to the vascular
surgical service by their general practitioner had no evidence
of PAD, which casts doubt on whether a positive initial
diagnosis of PAD can be made in primary care.
2. Many patients presented with bilateral symptoms of (near)
equal severity. Such patients are more suitable for systemic
therapy such as exercise or pharmacotherapy and not for a
lesion-focused therapy such as balloon angioplasty or
surgery.
3. Many patients had clear ideas about what treatment they did
and did not want. In particular, several patients did not want
to accept the small but nevertheless real risks of balloon
angioplasty, and for others, the requirement to commit to a
hospital-based supervised exercise program was a major
disincentive.
4. Many patients who gave a clear history of exercise-limiting
intermittent claudication were unable for a variety of reasons
to reproduce their symptoms and estimated maximal walking
distance on a standard treadmill test.
5. Many clinically eligible patients did not have a pattern of
disease that is suitable for balloon angioplasty. It would have
been possible to increase the numbers of patients in the trial
by accepting more TASC category D lesions. However, the
investigators and participating radiologists believed this
would almost certainly have led to a much higher rate of
balloon angioplasty failure and complications.
Fig. Consort diagram to illustrate pathway of patients during their assessment for eligibility for randomization into the
EXACT trial. PAD, Peripheral arterial disease; SE, supervised exercise; BA, balloon angioplasty; MWD, maximal
walking distance; BMT, best medical therapy.
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6. Last but not least, many of the relatively few eligible patients
simply did not want to enter the trial after 3-6 months on
best medical treatment. This is perhaps not surprising, given
that intermittent claudication tends to affect an elderly pop-
ulation, who are often socioeconomically disadvantaged and
have other comorbidity.
Unfortunately, the premature closure of EXACT means
that for the foreseeable future, clinicians will continue to have
little or no evidence regarding the adjuvant treatment of infrain-
guinal intermittent claudication. The question is whether a
randomized-controlled trial to compare supervised exercise and
balloon angioplasty in this condition is feasible and, if so,
affordable.
Simon D Hobbs, MBChB
Andrew W Bradbury, MD
Heart of England NHS Trust
University Department of Vascular Surgery
Lincoln House Heartlands Hospital
Birmingham, UK
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Regarding “Endovascular management of iliac artery
occlusions: Extending treatment to TASC C and D
lesions”
I read with great interest the report on the results of endovas-
cular recanalization of iliac artery occlusions by Leville et al.1 I had
the privilege of listening to its presentation in the Society for
Vascular Surgery Meeting in Chicago and have been anxiously
waiting for the written report. In addition, I had the privilege of
the floor and inquired about the wide discrepancy between the
limb salvage and patency rates, with limb salvage being significantly
lower than the patency rates in the TASC C and D groups.
Interestingly, when the report was published in the January 2006
issue of the Journal of Vascular Surgery, the patency and limb
salvage rates were very different. The 3-year primary patency,
secondary patency, and limb salvage rates, as presented and pub-
lished in the abstract book,2 were 88%, 92%, and 100% in TASC B;
82%, 97%, and 86% in TASC C; and 70%, 97%, and 62% in TASC
D lesions, whereas the corresponding numbers in the Journal of
Vascular Surgery article were 78%, 95%, and 100% in TASC B;
73%, 93%, and 97% in TASC C; and 80%, 83%, and 95% in TASC
D lesions. Although the number of patients treated for iliac disease
remained at 628 for both reports, those treated for occlusions
increased from 82 to 89. The number of legs treated increased
from 88 to 92, whereas the total number of amputations remained
at 2. Thus, these minor changes fail to explain the significant
differences in patency and limb salvage rates.
I am quite surprised at the wide discrepancy in the presenta-
tion and published article.When papers are presented in Society for
Vascular Surgery or other regional meetings, the impression is that
the paper is submitted at the time of presentation. Although it is
understandable to have someminor changes from the abstract, is it
really acceptable to come up with a whole new data set and
conclusions in the later publication? Maybe papers should not be
allowed to be presented in themeeting unless they are submitted in
advance to the program committee, to prevent inadequately ana-
lyzed data from being presented in prestigious meetings.
I wish to emphasize that I will continue to look forward to
studies coming from the well-respected institution reporting the
above study and have the utmost respect for all involved.2
Hasan H. Dosluoglu, MD
Department of Surgery
SUNY at Buffalo
VA Western NY Healthcare System
Buffalo, NY
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We appreciate Dr Dosluoglu’s interest in aortoiliac occlusive
disease and his keen reading of both the Society for Vascular
Surgery (SVS) abstract and the eventual Journal of Vascular Sur-
gery (JVS) publication. There is a discrepancy between the table in
the SVS abstract and Table II in the JVS publication. Initially, we
calculated limb-salvage rates by life-table analyses and included
four patients with transmetatarsal amputations. This was identified
and recalculated according to SVS criteria, dramatically increasing
limb salvage rates.1 Overall primary patency at 3 years was 76%, and
secondary patency was 90% according to Kaplan-Meier analyses—a
bit lower than the 77% and 95%, respectively, reported in the SVS
abstract. The changes in patency were due to adding an additional
seven patients to the analysis and having more complete follow-up
data on all patients.
We canunderstand any confusion thatmayhave arisenbecause of
the initial abstract table and Table II in the eventual publication. This
can occur in rigorously analyzing any dataset undergoing peer review.
However, we respectfully disagree that this represents coming upwith
“a whole new data and conclusions” (personal communication, April
3, 2006). The text and tables in the final JVS publication are correct.
The conclusions did not change. We hope that the message is clear
that endovascular recanalization of occluded iliac arteries can be
accomplished with high technical success rates, low morbidity, and
acceptable mid-term durability. In patients with aortoiliac occlusive
disease, correcting the concomitant femoral and infrainguinal disease
present extends the ability to treat this complex group of patients with
endovascular methods.
Vikram S. Kashyap, MD
Christopher D. Leville, MD
James F. Bena, MS
The Cleveland Clinic Foundation
Cleveland, Ohio
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